Tectonic Therapeutic, Inc. (TECX)
23.67
-0.45
(-1.87%)
USD |
NASDAQ |
Sep 25, 16:00
23.65
-0.02
(-0.08%)
After-Hours: 19:59
Tectonic Therapeutic Enterprise Value : 232.63M for Sept. 25, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 25, 2026 | 232.63M |
| September 24, 2026 | 241.28M |
| September 23, 2026 | 257.83M |
| September 22, 2026 | 287.06M |
| September 21, 2026 | 289.56M |
| September 18, 2026 | 296.68M |
| September 17, 2026 | 300.72M |
| September 16, 2026 | 314.19M |
| September 15, 2026 | 325.73M |
| September 14, 2026 | 348.81M |
| September 11, 2026 | 336.11M |
| September 10, 2026 | 327.65M |
| September 09, 2026 | 363.62M |
| September 08, 2026 | 362.08M |
| September 04, 2026 | 368.81M |
| September 03, 2026 | 352.85M |
| September 02, 2026 | 361.70M |
| September 01, 2026 | 377.85M |
| August 31, 2026 | 353.23M |
| August 28, 2026 | 462.49M |
| August 27, 2026 | 483.26M |
| August 26, 2026 | 469.22M |
| August 25, 2026 | 502.69M |
| August 24, 2026 | 478.84M |
| August 21, 2026 | 501.15M |
| Date | Value |
|---|---|
| August 20, 2026 | 470.76M |
| August 19, 2026 | 489.80M |
| August 18, 2026 | 481.53M |
| August 17, 2026 | 428.44M |
| August 14, 2026 | 448.83M |
| August 13, 2026 | 430.94M |
| August 12, 2026 | 485.76M |
| August 11, 2026 | 390.36M |
| August 10, 2026 | 406.51M |
| August 07, 2026 | 373.24M |
| August 06, 2026 | 358.62M |
| August 05, 2026 | 345.92M |
| August 04, 2026 | 338.42M |
| August 03, 2026 | 314.38M |
| July 31, 2026 | 316.49M |
| July 30, 2026 | 325.73M |
| July 29, 2026 | 324.19M |
| July 28, 2026 | 350.54M |
| July 27, 2026 | 366.12M |
| July 24, 2026 | 361.50M |
| July 23, 2026 | 385.36M |
| July 22, 2026 | 384.97M |
| July 21, 2026 | 408.25M |
| July 20, 2026 | 394.20M |
| July 17, 2026 | 404.40M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.677B |
| Alnylam Pharmaceuticals, Inc. | 33.91B |
| Anika Therapeutics, Inc. | 259.45M |
| Savara, Inc. | 884.37M |
| Vericel Corp. | 1.964B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -22.28M |
| Total Expenses (Quarterly) | 22.28M |
| EPS Diluted (Quarterly) | -1.175 |
| Earnings Yield | -19.28% |
| Normalized Earnings Yield | -19.28 |